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Mycophenolate versus 
azathioprine as maintenance 
therapy for lupus nephritis
Dooley et al., N Engl J Med 2011; 365: 1886–1895; doi:10.1056/
NEJMoa1014460
Although there is relatively effective induction therapy for severe 
lupus nephritis, optimal maintenance therapy is still being inves-
tigated. Previously, it had been shown that, following short-term 
induction therapy with intravenous cyclophosphamide (IVC), 
maintenance therapy with mycophenolate mofetil (MMF) or aza-
thioprine (AZA) was more efficacious than long-term IVC,1 and in 
a second study,2 following an attenuated IVC regimen, MMF was 
shown to be equally as efficacious as AZA in maintaining remis-
sion. Now, we have another study comparing AZA with MMF as 
maintenance therapy in patients with proliferative lupus nephritis. 
This is an extension of the previously published Aspreva Lupus 
Management Study (ALMS),3 which had shown that MMF was not 
superior to IVC in inducing remission. In this maintenance study 
(116 on MMF and 111 on AZA), MMF was superior to AZA with 
respect to the primary end point, time to treatment failure (hazard 
ratio, 0.44; 95% confidence interval, 0.25–0.77). MMF was also 
superior with respect to secondary end points, time to renal flare 
and time to rescue therapy (hazard ratio, <1.00). Minor treatment-
related adverse events were common, with infections and gastro-
intestinal disorders occurring in more than 95% of the patients in 
both groups. Serious adverse events occurred in 33% of the patients 
in the AZA group and in 24% of those in the MMF group, and the 
rate of withdrawal due to adverse events was higher with AZA than 
with MMF (40% versus 25%).
The strengths of the ALMS maintenance trial were the large 
number of patients and the multiethnic cohort. Unanswered ques-
tions remain, as pharmacokinetics data were not available and sub-
group analysis to see whether particular groups of patients would 
benefit from AZA was not possible because of sample-size issues, 
length of therapy, and corticosteroid dose and duration. Regard-
less, MMF now appears to be an established agent in induction and 
maintenance therapy for severe lupus nephritis.
Jai Radhakrishnan
1N Engl J Med 2004; 350: 971–980. 2Ann Rheum Dis 2010; 69: 2083–2089. 3J Am Soc 
Nephrol 2009; 20: 1103–1112.
INF2 mutations in Charcot–Marie–
Tooth disease with glomerulopathy
Boyer et al., N Engl J Med 2011; 365: 2377–2388; doi:10.1056/NEJMoa1109122
Charcot–Marie–Tooth (CMT) neuropathy is one of the most 
common forms of inherited neuropathy and can occur as a 
result of mutations in at least 40 different genes. This disease is 
characterized by progressive motor neuropathy affecting limb 
muscles, and patients typically develop sensory abnormalities. 
CMT neuro pathy can occur as a result of either abnormalities of 
axonal function or abnormal myelination of axons by Schwann 
cells. Its clinical manifestations can vary considerably, and there 
have been several reports of proteinuric kidney neuropathy 
occurring in patients with CMT neuropathy, the most common 
renal pathologic lesion being focal segmental glomerulosclerosis 
(FSGS). Until now, the molecular mechanisms linking CMT neu-
ropathy and FSGS pathogenesis were unknown. Since mutations 
in INF2 have recently been shown to cause autosomal dominant 
FSGS, and INF2 can interact with the Rho-GTPase CDC42 and 
myelin and lymphocyte protein (MAL), which are important 
factors in myelin formation and maintenance, Boyer et al. tested 
the hypothesis that INF2 may be responsible for cases of CMT 
neuropathy associated with FSGS. The investigators genotyped 
INF2 in 16 patients with CMT neuropathy and FSGS who did 
not have mutations in genes commonly associated with CMT 
neuropathy. The authors identified nine new heterozygous muta-
tions in 12 of the 16 patients who presented with an intermediate 
form of CMT neuropathy as well as a glomerulopathy with FSGS 
on kidney biopsy. All mutations were located in exons encoding 
the diaphanous-inhibitory domain of INF2. Immunostaining 
demonstrated that INF2 was present in Schwann-cell cytoplasm 
and podocytes. Moreover, the authors demonstrated that INF2 
colocalizes and interacts with MAL in Schwann cells (Figure). 
Mutations in INF2 disrupted the INF2–MAL–CDC42 pathway, 
resulting in cytoskeleton disorganization, enhanced INF2 bind-
ing to CDC42, and mislocalization of INF2, MAL, and CDC42.
This study demonstrates that INF2 is important for normal func-
tion of podocytes and Schwann cells and that mutations in INF2 
can cause FSGS-associated CMT neuropathy. Also, this paper is 
particularly interesting because although several podocyte proteins 
have been demonstrated to have important roles in the biology of 
neuronal cells, this is the first report of a podocyte protein that influ-
ences neuronal function via its role in Schwann cells. Perhaps these 
results should not surprise, given that both podocytes and Schwann 
cells use highly specialized cytoskeletal architecture to wrap capil-
laries and neurons, respectively.
Michael Ross
MAL, INF2, and MAL2 proteins in normal human kidney specimens and 
peripheral nerve biopsy specimens. The serial sections shown suggest 
that INF2 colocalizes with MAL2 in podocytes and MAL in Schwann cells.
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Reverse signaling through the 
costimulatory ligand CD137L  
in epithelial cells is essential  
for natural killer cell–mediated  
acute tissue inflammation
Kim et al., Proc Natl Acad Sci USA 2012; 109: E13–E22; doi:10.1073/
pnas.1112256109
The innate immune system is composed of inflammatory cells such 
as dendritic cells, macrophages, neutrophils, natural killer T cells, 
and natural killer (NK) cells that contribute to an inflammatory 
cascade leading to renal epithelial-cell apoptosis and necrosis fol-
lowing kidney ischemia–reperfusion injury (IRI) (Figure). Dying 
cells release endogenous molecules called damage/danger-associ-
ated molecular patterns that activate the immune system. These 
molecules activate immune cells, resulting in the recruitment of 
neutrophils, a key mediator of tissue injury.
Following kidney IRI, NK cells directly kill tubular epithelial 
cells (TECs) through interactions between the NKG2D receptor 
on NK cells and Rae-1 on TECs in a perforin-dependent manner. 
Kim et al. add new insight into the role of NK cells in kidney IRI 
by demonstrating the critical role of CD137L–CD137 signaling. 
In classical adaptive immunity, CD137L expressed on antigen-
presenting cells can costimulate CD137 on T cells, but there are 
also data that suggest that CD137L–CD137 signaling is important 
in innate immunity. Through reverse signaling, antigen-present-
ing cells expressing CD137L can be activated by NK-cell CD137 
to secrete cytokines and chemokines. The authors demonstrated 
that CD137L is expressed on TECs, and the absence of CD137 in 
mice reduced kidney IRI. Recombinant CD137 crystallizable frag-
ment (Fc) fusion protein engages TEC CD137L to secrete CXCL1 
and CXCL2 and, when administered systemically, induces more 
injury following IR. The proof in vivo that epithelial-cell CD137L 
activation induced injury comes from the study in which wild-type 
TECs were implanted in CD137L knockout mice below the renal 
capsule. In CD137L knockout mice, which are normally protected 
from IRI, implantation of wild-type TECs led to IRI-induced 
NK-cell CD137 expression, and transfer of NK cells into CD137 
knockout mice reconstituted injury and induced high levels of func-
tional CXCL1 and CXCL2. Thus, these results reveal that NK cells, 
through CD137L–CD137 reverse signaling, promote tissue injury 
by enhancing chemokine production, leading to neutrophil infiltra-
tion and inflammation. This study defines a novel mechanism that 
may be exploited therapeutically.
Mark Okusa
Rapid, persistent action of  
Tregs depends on blockade  
of intracellular calcium release
Schmidt et al., Sci Signal 2011; 4: ra90; doi:10.1126/scisignal.2002179
Regulatory CD4+CD25+ FOXP3-expressing T cells (Tregs) have 
been the object of extensive research in recent years, but the pre-
cise molecular mechanisms of their action remain to be fully eluci-
dated. With respect to the kidney, Tregs may have beneficial effects 
in transplant rejection, immune-mediated glomerulonephritis, and 
renal cancer, by directly inhibiting the proliferation of CD4+CD25− 
T lymphocytes and their production of effector cytokines. In their 
study, Schmidt and collaborators describe a rapid but persistent 
mechanism of inhibition of cytokine production by Tregs on 
CD4+CD25– T lymphocytes that relies on inhibition of calcium 
release from intracellular stores. 
The authors demonstrate that preactivated Tregs need only a 
very short period (30–45 minutes) of coculture with CD4+CD25– 
T lymphocytes to inhibit calcium signaling and consequently 
suppress their signaling machinery. Suppressed CD4+CD25– 
T lymphocytes are unable to activate NF-kB and NFAT1 sig-
naling pathways, which consequently prevents the expression of 
cytokine-encoding genes. In contrast, Ca2+-independent events, 
such as T-cell receptor (TCR)-proximal signaling and activation 
of the transcription factor AP-1, are not affected. Therefore, these 
results elucidate a previously unrecognized and rapid mechanism 
of Treg-mediated suppression and suggest that at least two differ-
ent mechanisms of suppression of human CD4+CD25– T lym-
phocytes might operate. First, rapid suppression of Ca2+, NFAT, 
and NF-kB signaling might result in inhibition of cytokine pro-
duction, which is maintained upon removal of Tregs and seems 
to be independent of cytotoxic T-lymphocyte-associated antigen 
4 (CTLA-4) and antigen-presenting cells. Second, suppression of 
the proliferation of human CD4+CD25– T lymphocytes might 
require prolonged contact with Tregs and may be independent 
of Ca2+ signaling and the suppression of cytokine production.
Several questions remain open. Most importantly, the exact sig-
naling events that lead to inhibition of Ca2+ release remain to be 
determined. Also, CTLA-4 and TCRs excluded, the receptor that 
mediates these rapid effects remains to be shown. 
Maria Pia Rastaldi
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The costimulatory ligand CD137L in epithelial cells is essential for 
natural killer (NK) cell–mediated acute tissue inflammation.  Following 
ischemia-reperfusion, NK cells infiltrate into the kidney and through cell 
surface CD137 stimulate proximal tubule epithelial cells through their 
cell surface ligand CD137L. CD137 signaling leads to the production of 
chemokines CXCL1 and CXCL2 (CXCL1,2) and chemotaxis of neutrophils. 
Neutrophils participate in tissue inflammation and injury.
